Navigation Links
Haemonetics Reports 2nd Quarter Fiscal 2014 Revenue Up 8%; Adjusted Operating Margin Up 260 Basis Points; and $0.66 Adjusted EPS Up 24%
Date:10/28/2013

down $1.4 million or 18%.  Recent market trends toward the adoption of tranexamic acid to treat and prevent post-operative blood loss continued to lessen hospital use of OrthoPAT disposables.

Diagnostics revenue was $8.0 million for the quarter, up $1.0 million or 15%.
On the strength of a TEG® Thromboelastograph® Hemostasis Analyzer installed base that is up 22% from a year ago, prospects for near term future disposables revenue growth continue to be robust.

Software and Equipment

Software Solutions revenue was $17.1 million for the quarter, down $0.9 million or 5%.  The pipeline of BloodTrack® and other blood management software opportunities is robust and expected to drive revenue growth in the back half of the year.

Equipment and other revenue was $14.9 million for the quarter, up $0.6 million or 4%.  Equipment revenue is influenced by the timing of tenders and capital budgets.

Geographic

Haemonetics reported second quarter organic revenue growth of 4% in North America and 26% in Asia Pacific, with declines of 9% in Europe and 16% in Japan.  Growth in North America was driven by strength in the Plasma business and growth in Asia Pacific was attributable to the change to a direct business model in Australia and New Zealand, as well as strength in China and other emerging markets.  The decline in Europe was due primarily to the aggressive return of the surgical competitor to the market.  Weakness in the Yen exchange rate contributed 9% of the 16% decline in second quarter Japan revenue.

OPERATING RESULTSAdjusted gross profit was $123.4 million, up $11.8 million or 11% in the quarter.  Adjusted gross margin was 52.3%, up 120 basis points.  Gross margin improvement in the base business, driven by productivity programs yielding cost efficiencies, more than offset the impact of revenue mix toward lower margin whole blood and plas
'/>"/>

SOURCE Haemonetics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related medicine technology :

1. FDA Approvals, Dividends, New Technologies, and Solid Margins Increase Shareholder Value - Research Report on Abbott, Baxter, CareFusion, Haemonetics, and CR Bard
2. Haemonetics Reports 1st Quarter Fiscal 2014 Revenue Up 24%; Adjusted EPS of $0.46 Up 46%; Adjusted Operating Margin Improvement of 270 Basis Points; and Significant Progress on Planned Manufacturing Transformation
3. The Zacks Analyst Blog Highlights: Walgreens, Express Scripts Holding, Haemonetics, ResMed and Eli Lilly
4. Haemonetics Announces Next Steps in Manufacturing Transformation
5. Haemonetics to Present at The Deutsche Bank 38th Annual dbAccess Health Care Conference
6. Haemonetics Completes Hemerus Medical, LLC Acquisition
7. Haemonetics Reports 4th Quarter Fiscal 2013 Revenue Up 34% and Adjusted EPS of $0.48; Fourth Quarter and Full Year Organic Revenue Up 4% and Full Year Adjusted EPS of $1.71; Completes Hemerus Medical, LLC Acquisition and Provides Fiscal 2014 Guidanc
8. Haemonetics Sets Date for Investor/Analyst Meeting
9. Haemonetics Reports 3rd Quarter Fiscal 2013 Revenue Up 29% and $0.50 Adjusted EPS; Year-To-Date Organic Revenue Up 3%; Reaffirms Fiscal 2013 Adjusted EPS Guidance of $1.65-$1.70
10. Haemonetics Provides Update on Hemerus Medical, LLC Acquisition
11. Haemonetics Completes Acquisition of Palls Transfusion Medicine Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 KaloBios Pharmaceuticals, Inc. (Nasdaq: ... of the KB001-A development program, including an update on ... KB001-A Collaboration Update KaloBios announced that ... regain all rights to KaloBios, KB001-A program. Under this ... 2010 has been terminated. Under that collaboration agreement, Sanofi ...
(Date:7/28/2014)... July 28, 2014  Serco Inc., a provider ... Company has been awarded a re-compete contract to ... and its Deployable Medical Systems.  Serco will provide ... to provide world-class healthcare to meet warfighter and ... the globe. The five year contract has a ...
(Date:7/28/2014)... Colo. , July 28, 2014  Array ... financial results for the fourth quarter and ... a conference call to discuss those results ... Chief Executive Officer and Michael Carruthers ... call.Conference Call InformationDate:Tuesday, August 12, 2014Time:9:00 a.m. ...
Breaking Medicine Technology:KaloBios Provides Update on KB001-A Partnership and Clinical Status 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 3KaloBios Provides Update on KB001-A Partnership and Clinical Status 4KaloBios Provides Update on KB001-A Partnership and Clinical Status 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 6Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... -First Combination Study of a MET and EGFR Inhibitor-, ... (Nasdaq: EXEL ) today announced that it has ... non-small cell lung cancer (NSCLC) who have had,progressive disease ... a small molecule that simultaneously inhibits the MET, RET ...
... ASHBURN, Va., Jan. 4 Innocoll, Inc., ... first of a series of,planned phase 2 ... subsidiary,Innocoll Technologies Ltd, to investigate CollaRx(R) BUPIVACAINE ... has commenced dosing., Innocoll,s BUPIVACAINE SURGICAL ...
Cached Medicine Technology:Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 2Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 3Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer 4Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-operative Pain 4
(Date:7/28/2014)... Camp Soaring Eagle today announced it ... Cornville, AZ. The nonprofit organization, founded in July ... to attend medically supervised camps at no cost ... a variety of programs to Arizona families and ... illnesses including: Illness Specific Camping Weekends, Illness Specific ...
(Date:7/28/2014)... WI (PRWEB) July 28, 2014 Quincy ... Prevagen® , is pleased to announce the release of ... by company president and co-founder Mark Underwood. , The ... health information, offering useful techniques for readers to improve ... as an unavoidable conclusion, The Brain Health Guide provides ...
(Date:7/28/2014)... Randy Dotinga HealthDay Reporter ... know it takes humans just milliseconds to look at someone,s ... a new study finds that certain facial features seem to ... The shape and size of the mouth, for example, appear ... are keys to attractiveness. The study findings suggest ...
(Date:7/28/2014)... Ticket Down is reliable source for ... TX at the Cotton Bowl. The 2014 Guinness International ... it is an eight team tourney. The tournament participants ... from La Liga, Serie A, English Premier League, and Superleague ... on the pitch include: Manchester United, Manchester City, Olympiacos, ...
(Date:7/28/2014)... Glutamine is the most abundant single ... be conditionally essential during times when the body undergoes ... & Immune System Support. , Having a heavy work ... supplementing with additional glutamine may be advantageous. Glutamine supplementation ... body, digestion and immune system function. Stress on the ...
Breaking Medicine News(10 mins):Health News:Camp Soaring Eagle Announces New Camp Site 2Health News:Camp Soaring Eagle Announces New Camp Site 3Health News:Quincy Bioscience Launches the Fourth Edition of The Brain Health Guide 2Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 2Health News:Real Madrid vs. AS Roma Tickets Cotton Bowl Dallas, TX: Ticket Down Cuts Ticket Prices for AS Roma vs. Real Madrid International Champions Cup Tickets 3Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... ADHD who carry a specific type of dopamine ... (MPH) than those without the genotype, according to ... The findings come from the first-ever placebo-controlled ... school age children to evaluate variants of the ...
... took the banned substance were leaner and ran faster, ... hormone, a substance frequently implicated in sports doping scandals, ... shows. , Australian researchers gave 96 non-professional athletes aged ... saline placebo. Participants included 63 men and 33 women. ...
... NEW ORLEANS, LA (May 3, 2010) Researchers have ... bowel disease, while other science shows that intra-abdominal fat ... patients, and new technology shows promising results for improvements ... the studies being presented at Digestive Disease Week (DDW) ...
... 2010) The results of new research results published ... the American College of Surgeons show that a ... hospital surgical ward. Postoperative pneumonia is a ... most common infectious complication after urinary tract and wound ...
... and without symptoms, screening mammography may be inappropriate, researchers say ... under the age of 40 result in many return visits ... a new study finds. , Almost 30 percent of ... getting mammograms, although they,re not generally recommended until age 40. ...
... later outcomes, studies show , MONDAY, May 3 (HealthDay ... critical prenatal, maternal and environmental factors can be in shaping ... things, the studies found that kids who stayed glued to ... who smoked or took antidepressants during pregnancy had raised risks ...
Cached Medicine News:Health News:Research helps end guesswork in prescribing ADHD drug 2Health News:Human Growth Hormone Does Boost Athletic Performance 2Health News:Human Growth Hormone Does Boost Athletic Performance 3Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 2Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 3Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 4Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 5Health News:Pancreatic cancer: Minimally invasive treatments and possible links to GI diseases 6Health News:Surgeons' pilot prevention program reduces incidence of postoperative pneumonia 2Health News:Effects of TV, Drug Exposures in Early Life May Be Long-Lasting 2Health News:Effects of TV, Drug Exposures in Early Life May Be Long-Lasting 3
... ORTHOSTAR table is the most ... It was designed for both ... traction with an integrated shoulder ... special purpose operating table for ...
... theatre is ready for all current and future ... design allows a quick, problem-free conversion to meet ... connected securely and sturdily to MARS through a ... should ever be a problem in spite of ...
... Exclusive, 210° Top Rotation provides ... purpose surgery. The Hercules 6700B eliminates ... during head-end procedures, while providing ample ... to sit during procedures. Removable back ...
... schaereraxis 200/300 product range includes ... been designed for the varied ... in the surgical practice, in ... A favorable price-performance ratio takes ...
Medicine Products: